NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

MeiraGTx Holdings plc (MGTX) Stock Analysis

MeiraGTx Holdings plc (MGTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MGTX

$13.89

−$0.08 (−0.57%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MGTX with… →

MGTX Key Statistics

As of Sep 4, 2026
Trading
Open
$13.70
Previous Close
$13.97
Day's Range
13.60–14.05
52-Week Range
6.62–15.35
Volume
531.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.27
Valuation
Market Cap
$1.33B
P/E Ratio
15.97
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.36
EPS (ttm)Profit attributable to each share over the last twelve months.
0.87
Financials (FY)
Revenue (FY)
$81.39M+144.57%
Net Income (FY)
−$114.20M
Profit marginThe share of revenue left as profit after all costs and taxes.
19.87%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
96.04M
1-Year Return
+79.92%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
848.60K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MGTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+74.72%
2025+30.54%
2024−13.25%
2023+7.67%
2022−72.54%
2021+56.80%
2020−24.38%
2019+107.68%
2018 (partial year)−35.73%

As of September 4, 2026.

MGTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$81.39M−$114.20M−140.3%
2024$33.28M−$147.79M−444.1%
2023$14.02M−$84.03M−599.5%
2022$15.92M−$129.62M−814.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$81.39M$76.55M−$105.97M−$114.20M−140.3%
2024$33.28M$9.49M−$164.21M−$147.79M−444.1%
2023$14.02M$14.02M−$137.06M−$84.03M−599.5%
2022$15.92M—−$116.36M−$129.62M−814.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MGTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricMGTXBiotechnology medianvs median
P/E15.9712.5727% above
P/S ratio3.3615.260.2x the median
Profit margin19.87%0.00%19.9 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values MeiraGTx Holdings plc (MGTX) at $1.33B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 393 employees.

Over the past 52 weeks the price has ranged from $6.62 to $15.35. MGTX last closed at $13.89 on September 4, 2026. That is −$0.08 (−0.57%) against the previous close. The latest close sits 109.82% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $81.39M. Against the prior fiscal year total of $33.28M, that is a change of +144.57%. The same year closed with a net loss of $114.20M. The reported profit margin is 19.87%. That is 19.9 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 0.87.

Across the 4 fiscal years on file, revenue moves from $15.92M in 2022 to $81.39M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

MGTX trades at a trailing price-to-earnings ratio of 15.97. That is 27.05% above the Biotechnology median of 12.57. Measured against sales, the shares trade at 3.36 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.27. Annualized volatility over the trailing 8 years is 66.43%. Over the trailing twelve months the price has returned +79.92%. Across 5 years the annualized return works out at +2.36%.

Growth & Income

The record shows no dividend for MGTX.

2026 is still running; the price is +74.72% year to date. Across the complete calendar years on file, 2019 returned +107.68% and 2022 returned −72.54%. Of the 7 complete calendar years on file, 4 finished higher.

Peer Comparison

MeiraGTx Holdings plc (MGTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MeiraGTx Holdings plc MGTX $1.33B 16.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. MeiraGTx Holdings plc trades at a P/E of 16.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MeiraGTx Holdings plc

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Visit website →